Regulation of Inflammatory Genes in Psoriasis

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03125655

Enrollment

Registered

2017-04-24

Start date

2014-04-22

Completion date

2028-04-28

Last updated

2026-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammation, Psoriasis

Keywords

cytokines

Brief summary

Psoriasis is a chronic and recurrent skin disorder characterized by marked inflammatory changes in the skin. An extensive cytokine network including generated by activated dendritic cells and T cells mediates the formation of psoriatic lesions. These immune-response parameters can be used as markers in the severity and management of the disease after further in-depth studies.

Interventions

DIAGNOSTIC_TESTInflammatory markers

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

19 Years to 99 Years

Healthy volunteers

Yes

Inclusion criteria

* Clinical diagnosis of psoriasis * Must be age 19 or older. * Must be Fitzpatrick skin type I, II, III, IV, V, VI.

Exclusion criteria

* Subjects who do not have photosensitive disease and are not on photosensitizing medications. * Subjects with a history of keloids (who are more likely to develop hypertrophic scars following skin biopsy). * Subjects who have an allergy to local anesthetics, antibiotics and/or anticoagulants. * Subjects who are pregnant.

Design outcomes

Primary

Measure	Time frame	Description
Inflammatory genes	1 day	TNF-alpha , IFN-alpha , IL-6, IL-8, IL-12 , IL-23, IL-4, IL-5 and IL-10

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 7, 2026